2-(3-氯苯氧基)-6-羟基苯乙酮 | 105277-74-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(3-氯苯氧基)-6-羟基苯乙酮
• 英文名称: 2-(3-chlorophenoxy)-6-hydroxyacetophenone
• 英文别名: 2-(3-chloropropoxy)-6-hydroxyacetophenone；6'-(3-chloropropoxy)-2'-hydroxy-acetophenone；1-[2-(3-chloropropoxy)-6-hydroxyphenyl]ethanone
• CAS: 105277-74-5
• 化学式: C₁₁H₁₃ClO₃
• 分子量: 228.675
• InChiKey: ONXYHYBXPRUQMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-氯苯氧基)-6-羟基苯乙酮 以 甲酸乙酯 为溶剂， 生成 5-(3-chloropropoxy)-4H-1-benzopyran-4-one
  参考文献：
  名称：

  4H-1-benzopyran-4-ones and their sulfur containing analogs

  摘要：

  揭示了一种有效治疗精神病，包括精神分裂症的Novel 4H-1-苯并吡喃-4-酮及其含硫类似物。

  公开号：

  US04678787A1
• 作为产物：
  描述：

  2,6-二羟基苯乙酮 、 1-溴-3-氯丙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以46%的产率得到2-(3-氯苯氧基)-6-羟基苯乙酮
  参考文献：
  名称：

  [EN] NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] NOUVEAUX DÉRIVÉS D'OXIMES ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE

  摘要：

  本发明提供了一般式（I）的新羟肟衍生物，包含它们的药物组合物以及它们用于治疗和/或预防与改变的谷氨酸信号和/或功能有关的疾病，和/或在哺乳动物中改变谷氨酸水平或信号会影响的疾病。本发明进一步提供了一般式（I）的新羟肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新羟肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。

  公开号：

  WO2011051478A1

文献信息

• Pyrimidinedione derivative compounds, method for preparing same, and
  申请人：Mitsui Toatsu Chemicals, Incorporated

  公开号：US05114941A1

  公开（公告）日：1992-05-19

  A pyrimidinedione derivative compound has a basic backbone in which a 4-oxobenzopyran ring group part and a pyrimidinedione part are linked by a structure comprising an alkyl chain containing at least two nitrogen atoms and one oxygen. The pyrimidinedione derivative is useful for a medical treatment of cardiac arrhythmias.

  一种嘧啶二酮衍生物化合物具有一种基本骨架，其中4-氧基苯并吡喃环团部分和嘧啶二酮部分通过含有至少两个氮原子和一个氧原子的烷基链结合。这种嘧啶二酮衍生物对治疗心律失常具有医疗用途。
• Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors
  申请人：Schann Stephan

  公开号：US20120277212A1

  公开（公告）日：2012-11-01

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.

  本发明提供了一般式（I）的新的肟衍生物，以及包含它们的制药组合物，以及它们用于治疗和/或预防与改变谷氨酸信号和/或功能相关的疾病和/或与哺乳动物中谷氨酸水平或信号改变有关的疾病的用途。本发明还提供了一般式（I）的新的肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新的肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向异构调节剂，更具体地说是mGluR4的正向异构调节剂。
• Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
  申请人：Schann Stephan

  公开号：US08962627B2

  公开（公告）日：2015-02-24

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.

  本发明提供了一般式（I）的新的肟衍生物、包含它们的药物组合物以及它们用于治疗和/或预防与改变谷氨酸信号和/或功能有关的疾病和/或可以受到哺乳动物谷氨酸水平或信号改变影响的疾病的用途。本发明还提供了一般式（I）的新的肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经系统和/或精神疾病。在特定实施例中，本发明的新的肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。
• Novel 4H-1-benzopyran-4-ones and their sulphur containing analogs
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0190015A1

  公开（公告）日：1986-08-06

  There are disclosed novel 4H -1-benzopyran-4-ones and their sulphur containing analogs which are effecacious for the treatment of psychosis including schizophrenia The compounds have the formula (I) wherein X is oxygen or sulfur, n is 2, 3, 4 or 5 and R is or in which Ar is an aryl.

  已公开的新型 4H -1- 苯并吡喃-4-酮及其含硫类似物可有效治疗包括精神分裂症在内的精神错乱。
• Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones
  作者：Juan C. Jaen、Lawrence D. Wise、Thomas G. Heffner、Thomas A. Pugsley、Leonard T. Meltzer

  DOI：10.1021/jm00105a039

  日期：1991.1

  The synthesis and pharmacological properties of a novel type of [(arylpiperazinyl)alkoxy]-4H-1-benzopyran-4-ones with dopaminergic activity are described. The nature of the arylpiperazine (AP) moiety determines the dopamine (DA) agonist/antagonist character of this series of compounds; when the aryl portion of the AP is unsubstituted the compounds appear to be DNA autoreceptor agonists while substituted aryl groups seem to impart DA antagonist activity. A heterocyclic piperazine, 7-[3-[4-(2-pyridinyl)-1-piperazinyl]propoxy]-4H-1-benzopyran-4-one (31, PD 119819) has been identified as an extremely selective DA autoreceptor agonist in tests that include [H-3]haloperiodol binding, inhibition of spontaneous locomotor activity, inhibition of brain DA synthesis, inhibition of brain DA neuronal firing, stereotypy assessment, and reversal of 6-hydroxydopamine (6-OHDA) induced akinesia in rats. In addition, 31 possesses good oral activity in the Sidman avoidance test in squirrel monkeys, a predictor of clinical antipsychotic efficacy. In another primate model, 31 has been found to lack the liability for extrapyramidal side effects observed with currently available antipsychotic drugs.